DelveInsight has launched a new report on Alzheimer’s disease Pipeline Insight, 2020
Alzheimer’s disease Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Alzheimer’s disease (AD) market. A detailed picture of the Alzheimer’s disease (AD) pipeline landscape is provided, which includes the disease overview and Alzheimer’s disease (AD) treatment guidelines. The assessment part of the report embraces in-depth Alzheimer’s disease (AD) commercial assessment and clinical assessment of the Alzheimer’s disease (AD) pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alzheimer’s disease (AD) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The Alzheimer’s disease (AD) market report provides current treatment practices, emerging drugs, Alzheimer’s disease (AD) market share of the individual therapies, current and forecasted Alzheimer’s disease (AD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Alzheimer’s disease (AD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. It is the most common cause of dementia (a continuous decline in thinking, behavioral and social skills that disrupts a person’s ability to function independently) accounting for ~60–80% of cases. The exact cause of Alzheimer’s disease is unknown, although a number of things are thought to increase your risk of developing the condition. These include increasing age, a family history of the condition, previous severe head injuries, and lifestyle factors and conditions associated with cardiovascular disease. The most common early symptom of Alzheimer’s is difficulty remembering newly learned information because Alzheimer’s changes typically begin in the part of the brain that affects learning.
Request for :- free sample page
Alzheimer’s disease (AD) of pipeline development activities
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Alzheimer’s disease (AD) with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Alzheimer’s disease (AD) treatment.
- Alzheimer’s disease (AD) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Alzheimer’s disease (AD) market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Alzheimer’s disease (AD) Analytical Perspective by DelveInsight
- In-depth Alzheimer’s disease (AD) Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
- Alzheimer’s disease (AD) Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Key companies are working on this disease that are given below:-
1. Lohmann Therapie- Systeme/ Novartis Pharma Co.
2. Green Valley Pharmaceuticals.
Name of drugs covered are given below:-
1. Report Introduction
2. Alzheimer’s disease (AD)
3. Alzheimer’s disease (AD) Current Treatment Patterns
3.1. Alzheimer’s disease (AD) Treatment Guidelines
4. Alzheimer’s disease (AD) – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Alzheimer’s disease (AD) Late Stage Products (Phase-III)
7. Alzheimer’s disease (AD) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Alzheimer’s disease (AD) Discontinued Products
13. Alzheimer’s disease (AD) Product Profiles
14. Alzheimer’s disease (AD) Key Companies
15. Alzheimer’s disease (AD) Key Products
16. Dormant and Discontinued Products
17. Alzheimer’s disease (AD) Unmet Needs
18. Alzheimer’s disease (AD) Future Perspectives
19. Alzheimer’s disease (AD) Analyst Review
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
22. About Delveinsight
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States